 NEW YORK, Aug. 30, 2022 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced the presentations it will be making at investor and scientific conferences in September 2022. 